glp-1 kidney disease ICYMI: Agonists Show Promise in Slowing in Lupus Nephritis GLP-1 receptor agonists and next-generation

While semaglutide has become one of the most recognized weight loss medications available today, retatrutide has generated excitement because of its unique mechanism of action and impressive clinical trial results

The most significant data comes from the REDEFINE trials, evaluating the co-administration of Cagrilintide and Semaglutide These findings highlight the synergistic potential of combining the amylin pathway (Cagrilintide) and the GLP-1 pathway (Semaglutide) to achieve superior metabolic and weight loss outcomes compared to either agent alone

In terms of compatibility, GHK-Cu works well with hydrating agents such as hyaluronic acid and barrier-support ingredients

A novel stomach pentadecapeptide, BPC-157, improves wound and fracture healing in rats in addition to having an angiogenic effect